Development of a Bioavailable μ Opioid Receptor (MOPr) Agonist, δ Opioid Receptor (DOPr) Antagonist Peptide That Evokes Antinociception without Development of Acute Tolerance

[Image: see text] We have previously described a cyclic tetrapeptide, 1, that displays μ opioid receptor (MOPr) agonist and δ opioid receptor (DOPr) antagonist activity, a profile associated with a reduced incidence of opioid tolerance and dependence. Like many peptides, 1 has poor bioavailability....

Descripción completa

Detalles Bibliográficos
Autores principales: Mosberg, Henry I., Yeomans, Larisa, Anand, Jessica P., Porter, Vanessa, Sobczyk-Kojiro, Katarzyna, Traynor, John R., Jutkiewicz, Emily M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2014
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3993928/
https://www.ncbi.nlm.nih.gov/pubmed/24641190
http://dx.doi.org/10.1021/jm5002088

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3993928/
https://www.ncbi.nlm.nih.gov/pubmed/24641190
http://dx.doi.org/10.1021/jm5002088

Ejemplares similares